Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

Effects of β-adrenoceptor subtypes on cardiac function in myocardial infarction rats exposed to fine particulate matter (PM 2.5).

Gao Y, Lv J, Lin Y, Li X, Wang L, Yin Y, Liu Y.

Biomed Res Int. 2014;2014:308295. doi: 10.1155/2014/308295. Epub 2014 Aug 12.

2.

Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees Investigators.

Eur J Heart Fail. 2014 Jul;16(7):817-25. doi: 10.1002/ejhf.115. Epub 2014 Jun 3.

3.

The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction.

Ketchum ES, Dickstein K, Kjekshus J, Pitt B, Wong MF, Linker DT, Levy WC.

Eur Heart J Acute Cardiovasc Care. 2014 Mar;3(1):46-55. doi: 10.1177/2048872613502283. Epub 2013 Sep 11.

4.

Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.

Shah AM, Shah SJ, Anand IS, Sweitzer NK, O'Meara E, Heitner JF, Sopko G, Li G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD; TOPCAT Investigators.

Circ Heart Fail. 2014 Jan;7(1):104-15. doi: 10.1161/CIRCHEARTFAILURE.113.000887. Epub 2013 Nov 18.

5.

Prevention of liver cancer cachexia-induced cardiac wasting and heart failure.

Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, Kaschina E, Palus S, Pötsch M, von Websky K, Hocher B, Latouche C, Jaisser F, Morawietz L, Coats AJ, Beadle J, Argiles JM, Thum T, Földes G, Doehner W, Hilfiker-Kleiner D, Force T, Anker SD.

Eur Heart J. 2014 Apr;35(14):932-41. doi: 10.1093/eurheartj/eht302. Epub 2013 Aug 29.

6.

Short-term outcomes in heart failure patients with chronic obstructive pulmonary disease in the community.

O'Kelly N, Robertson W, Smith J, Dexter J, Carroll-Hawkins C, Ghosh S.

World J Cardiol. 2012 Mar 26;4(3):66-71. doi: 10.4330/wjc.v4.i3.66.

7.

Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection.

Martin FL, McKie PM, Cataliotti A, Sangaralingham SJ, Korinek J, Huntley BK, Oehler EA, Harders GE, Ichiki T, Mangiafico S, Nath KA, Redfield MM, Chen HH, Burnett JC Jr.

Am J Physiol Regul Integr Comp Physiol. 2012 Jan 15;302(2):R292-9. doi: 10.1152/ajpregu.00194.2011. Epub 2011 Nov 9.

8.

Heart failure.

McKelvie RS.

BMJ Clin Evid. 2011 Aug 30;2011. pii: 0204.

9.

Relationships between emerging measures of heart failure processes of care and clinical outcomes.

Hernandez AF, Hammill BG, Peterson ED, Yancy CW, Schulman KA, Curtis LH, Fonarow GC.

Am Heart J. 2010 Mar;159(3):406-13. doi: 10.1016/j.ahj.2009.12.024.

10.

Heart failure.

McKelvie RS.

BMJ Clin Evid. 2010 Feb 25;2010. pii: 0204.

11.

Results of the ONTARGET and TRANSCEND studies: an update and discussion.

Fitchett D.

Vasc Health Risk Manag. 2009;5(1):21-9. Epub 2009 Apr 8. Review.

12.

Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.

Ecder T, Schrier RW.

Nat Rev Nephrol. 2009 Apr;5(4):221-8. doi: 10.1038/nrneph.2009.13. Review.

13.
14.

Valsartan in the treatment of heart attack survivors.

Jugdutt BI.

Vasc Health Risk Manag. 2006;2(2):125-38. Review.

15.

Coronary care medicine: it's not your father's CCU anymore.

Antman EM.

Trans Am Clin Climatol Assoc. 2004;115:123-34; discussion 134-5. Review.

16.

Lessons from the management of chronic heart failure.

McDonagh TA.

Heart. 2005 May;91 Suppl 2:ii24-7; discussion ii31, ii43-8. Review.

17.
18.
19.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk